WHAT THIS STUDY ADDS
REMISSION
This is an open-label multicentre, prospective and randomised controlled study aimed to evaluate the discontinuation of tofacitinib, a pan Janus kinase (JAK) inhibitor in patients who had achieved clinical remission, with a comparison of discontinuation of methotrexate (MTX). Approximately 60% of patients who discontinued tofacitinib relapsed, whereas 35% of patients relapsed after MTX discontinuation. The majority of patients who flare can again achieve remission following re-administration of tofacitinib.